The combination of AZD1775 with cisplatin sensitized squamous cell carcinoma of the head and neck (HNSCC) cells to the latter in in vitro and in vivo models; importantly, HNSCC cells carrying high-risk TP53 mutations became sensitive to cisplatin treatment by the selective WEE1 kinase inhibitor [252]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.